Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders

Drugs of the Future

Volumn 32, Issue 9, 2007, Pages 809-822

  Chaki, Shigeyuki ^a   Kanuma, Kosuke ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 2 [2 [2 (5 BROMO 2 METHOXYPHENYL)ETHYL] 3 FLUOROPHENYL] 4,5 DIHYDRO 1H IMIDAZOLE; 7 [4 (2,6 DICHLOROPHENYL) 1 PIPERIDINYLMETHYL] 6,7,8,9 TETRAHYDRO 1 METHYL 5H BENZOCYCLOHEPTEN 5 OL; AMG 076; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; ATC 0175; BENZOTHIOPHENE DERIVATIVE; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DITHIIN 1,1,4,4 TETROXIDE; FLUVOXAMINE; GALANIN; GW 3430; JNJ 2765074; MCL 0042; MCL 0129; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; N (6 DIMETHYLAMINOMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHYL) 4' FLUORO 1,1' BIPHENYL 4 CARBOXAMIDE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NGD 4715; RO 646198; SNAP 37889; SNAP 398299; SNAP 7941; SNAP 94847; UFP 101; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; BRAIN REGION; CLINICAL TRIAL; DEPRESSION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFECT; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; GENETIC ENGINEERING; HUMAN; LIGHT DARK CYCLE; NEUROMODULATION; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

EID: 36349015445     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.09.1131450     Document Type: Review

References (125)

1. Kramer, M.S., Cutler, N., Feighner, J. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281: 1640-5.
2. Keller, M., Montgomery, S., Ball, W. et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006, 59: 216-23.
3. Zobel, A.W., Nickel, T., Künzel, H.E., Ackl, N., Sonntag, A., Ising, M., Holsboer, F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 2000, 34: 171-81.
4. Aguilera, G., Rabadan-Diehl, C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: Implications for stress adaptation. Regul Pept 2000, 96: 23-9.
5. Purba, J.S., Hoogendijk, W.J., Hofman, M.A., Swaab, D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996, 53: 137-43.
6. van Londen, L., Goekoop, J.G., van Kempen, G.M., Frankhuijzen-Sierevogel, A.C., Wiegant, V.M., van der Velde, E.A., De Wied, D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17: 284-92.
7. Abelson, J.L., Le Melledo, J., Bichet, D.G. Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. Neuropsychopharmacology 2001, 24: 161-9.
8. Serradeil-Le Gal, C., Wagnon, J., Valette, G., Garcia, G., Pascal, M., Maffrand, J.P., Le Fur, G. Nonpeptide vasopressin receptor antagonists: Development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 2002, 139: 197-210.
9. Griebel, G., Stemmelin, J., Gal, C.S., Soubrie, P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 2005, 11: 1549-59.
10. Iijima, M., Chaki, S. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31: 622-7.
11. Louis, C., Cohen, C., Depoortere, R., Griebel, G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology 2006, 31: 2180-7.
12. Hodgson, R.A., Higgins, G.A., Guthrie, D.H. et al. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 2007, 86: 431-40.
13. Salome, N., Stemmelin, J., Cohen, C., Griebel, G. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl) 2006, 187: 237-44.
14. Stemmelin, J., Lukovic, L., Salome, N., Griebel, G. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 2005, 30: 35-42.
15. Shimazaki, T., Iijima, M., Chaki, S. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats. Eur J Pharmacol 2006, 543: 63-7.
16. Alonso, R., Griebel, G., Pavone, G., Stemmelin, J., Le Fur, G., Soubrie, P. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2004, 9: 278-86, 224.
17. Kawauchi, H., Kawazoe, I., Tsubokawa, M., Kishida, M., Baker, B.I. Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature 1983, 305: 321-3.
18. Bittencourt, J.C., Presse, F., Arias, C. et al. The melanin-concentrating hormone system of the rat brain: An immuno- and hybridization histochemical characterization. J Comp Neurol 1992, 319: 218-45.
19. Shimada, M., Tritos, N.A., Lowell, B.B., Flier, J.S., Maratos-Flier, E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998, 396: 670-4.
20. Georgescu, D., Sears, R.M., Hommel, J.D. et al. The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. J Neurosci 2005, 25: 2933-40.
21. Xu, Y.L., Jackson, V.R., Civelli, O. Orphan G protein-coupled receptors and obesity. Eur J Pharmacol 2004, 500: 243-53.
22. Roy, M., David, N.K., Danao, J.V., Baribault, H., Tian, H., Giorgetti, M. Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects. Neuropsychopharmacology 2006, 31: 112-20.
23. Roy, M., David, N., Cueva, M., Giorgetti, M. A study of the involvement of melanin-concentrating hormone receptor 1 (MCHR1) in murine models of depression. Biol Psychiatry 2007, 61: 174-80.
24. Smith, D.G., Davis, R.J., Rorick-Kehn, L. et al. Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology 2006, 31: 1135-45.
25. Smith, D.G., Tzavara, E.T., Shaw, J. et al. Mesolimbic dopamine super-sensitivity in melanin-concentrating hormone-1 receptor-deficient mice. J Neurosci 2005, 25: 914-22.
26. Kennedy, A.R., Todd, J.F., Dhillo, W.S. et al. Effect of direct injection of melanin-concentrating hormone into the paraventricular nucleus: Further evidence for a stimulatory role in the adrenal axis via SLC-1. J Neuroendocrinol 2003, 15: 268-72.
27. Borowsky, B., Durkin, M.M., Ogozalek, K. et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 2002, 8: 825-30.
28. Chaki, S., Funakoshi, T., Hirota-Okuno, S. et al. Anxiolytic-and antidepressant-like profile of ATC0065 and ATC0175: Nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J Pharmacol Exp Ther 2005, 313: 831-9.
29. Basso, A.M., Bratcher, N.A., Gallagher, K.B. et al. Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. Eur J Pharmacol 2006, 540: 115-20.
30. David, D.J., Kiemenhagen, K.C., Holick, K.A. et al. Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))- 4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J Pharmacol Exp Ther 2007, 321: 237-48.
31. Takekawa, S., Asami, A., Ishihara, Y. et al. T-226296: A novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol 2002, 438: 129-35.
32. Kanuma, K., Omodera, K., Nishiguchi, M. et al. Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett 2005, 15: 2565-9.
33. Kanuma, K., Omodera, K., Nishiguchi, M. et al. Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett 2005, 15: 3853-6.
34. Kanuma, K., Omodera, K., Nishiguchi, M. et al. Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem 2006, 14: 3307-19.
35. Tatemoto, K., Carlquist, M., Mutt, V. Neuropeptide Y - A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296: 659-60.
36. Heilig, M., Widerlov, E. Neuropeptide Y: An overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr Scand 1990, 82: 95-114.
37. Kask, A., Harro, J., von Horsten, S., Redrobe, J.P., Dumont, Y., Quirion, R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 2002, 26: 259-83.
38. Hashimoto, H., Onishi, H., Koide, S., Kai, T., Yamagami, S. Plasma neuropeptide Y in patients with major depressive disorder. Neurosci Lett 1996, 216: 57-60.
39. Nilsson, C., Karlsson, G., Blennow, K., Heilig, M., Ekman, R. Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients. Peptides 1996, 17: 359-62.
40. Heilig, M., Zachrisson, O., Thorsell, A. et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: Preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 2004, 38: 113-21.
41. Stein, M.B., Hauger, R.L., Dhalla, K.S., Chartier, M.J., Asmundson, G.J. Plasma neuropeptide Y in anxiety disorders: Findings in panic disorder and social phobia. Psychiatry Res 1996, 59: 183-8.
42. Widdowson, P.S., Ordway, G.A., Halaris, A.E. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 1992, 59: 73-80.
43. Nikisch, G., Agren, H., Eap, C.B., Czernik, A., Baumann, P., Mathe, A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 2005, 8: 403-10.
44. Mathe, A.A. Neuropeptides and electroconvulsive treatment. J ECT 1999, 15: 60-75.
45. Jimenez-Vasquez, P.A., Overstreet, D.H., Mathe, A.A. Neuropeptide Y in male and female brains of Flinders Sensitive Line, a rat model of depression. Effects of electroconvulsive stimuli. J Psychiatr Res 2000, 34: 405-12.
46. Mathe, A.A., Jimenez, P.A., Theodorsson, E., Stentors, C. Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded "depressed", Wistar, and Sprague Dawley rats. Effects of electroconvulsive stimuli. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22: 529-46.
47. Sergeyev, V., Fetissov, S., Mathe, A.A. et al. Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology (Berl) 2005, 178: 115-24.
48. Ishida, H., Shirayama, Y., Iwata, M., Kawahara, R. Subchronic treatment with imipramine ameliorates the decreased number in neuropeptide Y-positive cells in the hippocampus of learned helplessness rats. Brain Res 2005, 1046: 239-43.
49. Husum, H., Mathe, A.A. Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 2002, 27: 756-64.
50. Husum, H., Mikkelsen, J.D., Hogg, S., Mathe, A.A., Mork, A. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 2000, 39: 1463-73.
51. Bjornebekk, A, Mathe, A.A., Brene, S. Running has differential effects on NPY, opiates, and cell proliferation in an animal model of depression and controls. Neuropsychopharmacology 2006, 31: 256-64.
52. Britton, K.T., Southerland, S., Van Uden, E., Kirby, D., Rivier, J., Koob, G.. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology (Berl) 1997, 132: 6-13.
53. Goyal, S.N., Kokare, D.M., Chopde, C.T., Subhedar, N.K. Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats. Pharmacol Biochem Behav 2006, 85: 369-77.
54. Ishida, H., Shirayama, Y., Iwata, M., Katayama, S., Yamamoto, A., Kawahara, R., Nakagome, K. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 2007, 17: 271-80.
55. Bannon, A.W., Seda, J., Carmouche, M., Francis, J.M., Norman, M.H., Karbon, B., McCaleb, M.L. Behavioral characterization of neuropeptide Y knockout mice. Brain Res 2000, 868: 79-87.
56. Thorsell, A., Michalkiewicz, M., Dumont, Y. et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci USA 2000, 97: 12852-7.
57. Primeaux, S.D., Wilson, S.P., Cusick, M.C., York, D.A., Wilson, M.A. Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology 2005, 30: 1589-97.
58. Michel, M.C., Beck-Sickinger, A., Cox, H. et al. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998, 50: 143-50.
59. Kask, A., Rago, L., Harro, J. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: Antagonism with diazepam. Eur J Pharmacol 1996, 317: R3-4.
60. Thiele, T.E., Koh, M.T., Pedrazzini, T. Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J Neurosci 2002, 22: RC208.
61. Wahlestedt, C., Pich, E.M., Koob, G.F., Yee, F., Heilig, M. Modulation of anxiety and neuropeptide Y-Y1 receptors by anti-sense oligodeoxynucleotides. Science 1993, 259: 528-31.
62. Bacchi, F., Mathe, A.A., Jimenez, P., Stasi, L., Arban, R., Gerrard, P., Caberlotto, L. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 2006, 27: 3202-7.
63. Tschenett, A., Singewald, N., Carli, M. et al. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 2003, 18: 143-8.
64. 2 receptor antagonist. Eur J Pharmacol 1999, 384: R3-5.
65. 2 receptor. Bioorg Med Chem Lett 2003, 13: 2883-5.
66. 2 receptor antagonists. Bioorg Med Chem Lett 2004, 14: 1239-42.
67. Catania, A., Gatti, S., Colombo, G., Lipton, J.M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004, 56: 1-29.
68. Adan, R.A., Szklarczyk, A.W., Oosterom, J. et al. Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol 1999, 378: 249-58.
69. Chaki, S., Ogawa, S., Toda, Y., Funakoshi, T., Okuyama, S. Involvement of the melanocortin MC4 receptor in stress-related behavior in rodents. Eur J Pharmacol 2003, 474: 95-101.
70. Lu, X.Y., Barsh, G.S., Akil, H., Watson, S.J. Interaction between alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J Neurosci 2003, 23: 7863-72.
71. Kokare, D.M., Dandekar, M.P., Chopde, C.T., Subhedar, N. Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats. Brain Res 2005, 1043: 107-14.
72. Shimazaki, T., Chaki, S. Anxiolytic-like effect of a selective and non-peptidergic melanocortin 4 receptor antagonist, MCL0129, in a social interaction test. Pharmacol Biochem Behav 2005, 80: 395-400.
73. Chaki, S., Hirota, S., Funakoshi, T. et al. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4- isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J Pharmacol Exp Ther 2003, 304: 818-26.
74. Chaki, S., Oshida, Y., Ogawa, S. et al. MCL0042: A nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacol Biochem Behav 2005, 82: 621-6.
75. Arasasingham, P.N., Fotsch, C., Ouyang, X. et al. Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: Antagonists for the AGRP/melanocortin receptor binding. J Med Chem 2003, 46: 9-11.
76. Nozawa, D., Okubo, T., Ishii, T. et al. Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor. Bioorg Med Chem 2007, 15: 1989-2005.
77. Nozawa, D., Okubo, T., Ishii, T. et al. Novel piperazines: Potent melanocortin-4 receptor antagonists with anxiolytic-like activity. Bioorg Med Chem 2007, 15: 2375-85.
78. Vos, T.J., Caracoti, A., Che, J.L. et al. Identification of 2-{2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl}-4,5-dihydro-1H- imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 2004, 47: 1602-4.
79. Marsilje, T.H., Roses, J.B., Calderwood, E.F. et al. Synthesis and biological evaluation of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R). Bioorg Med Chem Lett 2004, 14: 3721-5.
80. Chen, C., Pontillo, J., Fleck, B.A. et al. 4-{(2R)-[3- Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl) ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist: Design, synthesis, and characterization. J Med Chem 2004, 47: 6821-30.
81. Pontillo, J., Tran, J.A., Fleck, B.A. et al. Piperazine-benzylamines as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2004, 14: 5605-9.
82. Pontillo, J., Tran, J.A., Markison, S. et al. A potent and selective nonpeptide antagonist of the melanocortin-4 receptor induces food intake in satiated mice. Bioorg Med Chem Lett 2005, 15: 2541-6.
83. Pontillo, J., Marinkovic, D., Tran, J.A. et al. Optimization of piperazinebenzylamines with a N-(1-methoxy-2-propyl) side chain as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2005, 15: 4615-8.
84. Jiang, W., Tucci, F.C., Chen, C.W. et al. Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2006, 16: 4674-8.
85. Tatemoto, K., Rokaeus, A., Jornvall, H., McDonald, T.J., Mutt, V. Galanin - A novel biologically active peptide from porcine intestine. FEBS Lett 1983, 164: 124-8.
86. Lu, X., Sharkey, L., Bartfai, T. The brain galanin receptors: Targets for novel antidepressant drugs. CNS Neurol Disord Drug Targets 2007, 6: 183-92.
87. Bing, O., Moller, C., Engel, J.A., Soderpalm, B., Heilig, M. Anxiolytic-like action of centrally administered galanin. Neurosci Lett 1993, 164: 17-20.
88. Moller, C., Sommer, W., Thorsell, A., Heilig, M. Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology 1999, 21: 507-12.
89. Weiss, J.M., Bonsall, R.W., Demetrikopoulos, M.K., Emery, M.S., West, C.H. Galanin: A significant role in depression? Ann NY Acad Sci 1998, 863: 364-82.
90. Bellido, I., Diaz-Cabiale, Z., Jimenez-Vasquez, P.A., Andbjer, B., Mathe, A.A., Fuxe, K. Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression. Neurosci Lett 2002, 317: 101-5.
91. Holmes, A., Li, Q., Koenig, E.A. et al. Phenotypic assessment of galanin overexpressing and galanin receptor R1 knockout mice in the tail suspension test for depression-related behavior. Psychopharmacology (Berl) 2005, 178: 276-85.
92. Swanson, C.J., Blackburn, T.P., Zhang, X. et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA 2005, 102: 17489-94.
93. Barr, A.M., Kinney, J.W., Hill, M.N., Lu, X., Biros, S., Rebek, J. Jr., Bartfai, T. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in pre-clinical tests. Neurosci Lett 2006, 405: 111-5.
94. Bartfai, T., Lu, X., Badie-Mahdavi, H. et al. Galmic, a non-peptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci USA 2004, 101: 10470-5.
95. Lu, X., Barr, A.M., Kinney, J.W., Sanna, P., Conti, B., Behrens, M.M., Bartfai, T. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc Natl Acad Sci USA 2005, 102: 874-9.
96. Holmes, A., Kinney, J.W., Wrenn, C.C. et al. Galanin GALR1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 2003, 28: 1031-44.
97. Gottsch, M.L., Zeng, H., Hohmann, J.G., Weinshenker, D., Clifton, D.K., Steiner, R.A. Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2). Mol Cell Biol 2005, 25: 4804-11.
98. Bailey, K.R., Pavlova, M.N., Rohde, A.D., Hohmann, J.G., Crawley, J.N. Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol Biochem Behav 2007, 86: 8-20.
99. Chu, M., Mierzwa, R., Truumees, I. et al. A new fungal metabolite, Sch 202596, with inhibitory activity in the galanin receptor GALR1 assay. Tetrahedron Lett 1997, 38: 6111-4.
100. Scott, M.K., Ross, T.M., Lee, D.H.S. et al. 2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: Small molecule non-peptide antagonists of the human galanin hGAL-1 receptor. Bioorg Med Chem 2000, 8: 1383-91.
101. 3 receptor antagonists. J Med Chem 2006, 49: 3757-8.
102. 3 receptor binding affinity and improved solubility. Bioorg Med Chem Lett 2006, 16: 3950-4.
103. Meunier, J.C., Mollereau, C., Toll, L. et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995, 377: 532-5.
104. Reinscheid, R.K., Nothacker, H.P., Bourson, A. et al. Orphanin FQ: A neuropeptide that activates an opioid-like G protein-coupled receptor. Science 1995, 270: 792-4.
105. Jenck, F., Moreau, J.L., Martin, J.R. et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci USA 1997, 94: 14854-8.
106. Griebel, G., Perrault, G., Sanger, D.J. Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res 1999, 836: 221-4.
107. Kamei, J., Matsunawa, Y., Miyata, S., Tanaka, S., Saitoh, A. Effects of nociceptin on the exploratory behavior of mice in the hole-board test. Eur J Pharmacol 2004, 489: 77-87.
108. Koster, A., Montkowski, A., Schulz, S. et al. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci USA 1999, 96: 10444-9.
109. Jenck, F., Wichmann, J., Dautzenberg, F.M. et al. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat. Proc Natl Acad Sci USA 2000, 97: 4938-43.
110. Varty, G.B., Hyde, L.A., Hodgson, R.A. et al. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) 2005, 182: 132-43.
111. Gavioli, E.C., Rizzi, A., Marzola, G., Zucchini, S., Regoli, D., Calo', G. Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice. Peptides 2007, 28: 1229-32.
112. Redrobe, J.P., Calo', G., Regoli, D., Quirion, R. Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn-Schmied Arch Pharmacol 2002, 365: 164-7.
113. Gavioli, E.C., Marzola, G., Guerrini, R. et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: Pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci 2003, 17: 1987-90.
114. Gavioli, E.C., Vaughan, C.W., Marzola, G. et al. Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: New evidence from rats and mice. Naunyn-Schmied Arch Pharmacol 2004, 369: 547-53.
115. Rizzi, A., Gavioli, E.C., Marzola, G. et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)-piperidin-1-yl]methyl]-6,7,8, 9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies. J Pharmacol Exp Ther 2007, 321: 968-74.
116. Marti, M., Stocchi, S., Paganini, F. et al. Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br J Pharmacol 2003, 138: 91-8.
117. Kawamoto, H., Ozaki, S., Itoh, Y. et al. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 1999, 42: 5061-3.
118. Shinkai,H., Ito, T., Iida, T. et al. 4-Aminoquinolines: Novel nociceptin antagonists with analgesic activity.. J Med Chem 2000, 43: 4667-77.
119. Zaratin, P.F., Petrone, G., Sbacchi, M. et al. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther 2004, 308: 454-61.
120. Benca, R.M., Obermeyer, W.H., Thisted, R.A., Gillin, J.C. Sleep and psychiatric disorders. A meta-analysis. Arch Gen Psychiatry 1992, 49: 651-68.
121. Berton, O., Nestler, E.J. New approaches to antidepressant drug discovery: Beyond monoamines. Nat Rev Neurosci 2006, 7: 137-51.
122. Asakawa, A., Inui, A., Kaga, T. et al. A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 2001, 74: 143-7.
123. Hanada, R., Nakazato, M., Murakami, N. et al. A role for neuromedin U in stress response. Biochem Biophys Res Commun 2001, 289: 225-8.
124. Suzuki, M., Beuckmann, C.T., Shikata, K., Ogura, H., Sawai, T. Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Res 2005, 1044: 116-21.
125. Xu, Y.L., Reinscheid, R.K., Huitron-Resendiz, S. et al. Neuropeptide S: A neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2004, 43: 487-97.